



Attorney Docket No.: 3985.240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: Havelund et al.

SEP 26 2002

Application No.: 09/398,365

Group Art Unit: 1637

TECH CENTER 1600 2900

Filed: September 17, 1999

Examiner: Siew, J.

Confirmation No: 9987

For: Acylated Insulin

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Commissioner for Patents
Box RCE
Washington, DC 20231

Sir:

This is a request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above identified application.

1. Submission required under 37 C.F.R. §1.114

a. ☐ Previously submitted

- i. ☐ Consider the amendment(s) reply under 37 C.F.R. §1.116 previously filed on
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on
- iii. ☐ Other

b. ☐ Enclosed

- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☒ Information Disclosure Statement (IDS)
- iv. ☐ Other

2. Miscellaneous

a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. §1.105(a) for _____ months.

b. ☐ Other

3. In the event that an extension of time is required, Applicant hereby petitions for such extension of time. If the Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account 14-1447.


4. Fees The RCE fee under 37 C.F.R. § 1.17 (e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

a. ☐ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit **Account No. 14-1447**. A duplicate copy of this sheet is attached.

- i. ☒ RCE fee required under 37 C.F.R. § 1.17 (e)
- ii. ☐ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
- iii. ☐ Other _____

Respectfully submitted,

Date: September 19, 2002


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 3985,240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Havelund et al.

Serial No.: 09/398,365

Group Art Unit: 1637

Filed: September 17, 1999

Examiner: Siew, J.

Confirmation No: 9987

For: Acylated Insulin

RECEIVED

SEP 26 2002

TECH CENTER 1600 2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box RCE
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References
4. Request for Continued Examination
5. Amendment

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on September 19, 2002.

Maya Faison-Phillip
(name of person mailing paper)